Ser165
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser165  -  SNIP iso5 (human)

Site Information
RMNRFRQsLPLsRSA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 481561

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 )
Disease tissue studied:
breast cancer ( 2 , 4 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 2 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 ) , lung cancer, surrounding tissue ( 5 )
Relevant cell line - cell type - tissue:
breast ( 1 , 2 ) , BT-20 (breast cell) ( 4 ) , H2009 (pulmonary) ( 4 ) , H2077 (pulmonary) ( 4 ) , H2887 (pulmonary) ( 4 ) , H322 (pulmonary) ( 4 ) , H322M (pulmonary) ( 4 ) , HCC1937 (breast cell) ( 4 ) , HOP62 (pulmonary) ( 4 ) , Jurkat (T lymphocyte) ( 6 ) , liver ( 3 ) , lung ( 5 ) , MCF-7 (breast cell) ( 4 ) , MDA-MB-468 (breast cell) ( 4 ) , NCI-H1395 (pulmonary) ( 4 ) , NCI-H2030 (pulmonary) ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

4

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

5

Tucker M (2011) CST Curation Set: 10951; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Possemato A (2007) CST Curation Set: 2451; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info